Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0290532 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Hye-Young Seo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, Institute for Medical Science, Keimyung University, Daegu, Korea. Hauptthemen laut MEDLINE: Inflammasomes, Liver Cirrhosis, Thiazolidinediones. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Liver inflammation is a common feature of chronic liver disease and is often associated with increased exposure of the liver to lipopolysaccharide (LPS). Kupffer cells (KCs) are macrophages in the liver and produce various cytokines. Activation of KCs through the NLRP3 inflammasome pathway leads to release of proinflammatory cytokines and induces hepatocyte injury and hepatic stellate cell (HSC) activation. Lobeglitazone is a peroxisome proliferator-activated receptor gamma ligand and a type of thiazolidinedione that elicits anti-inflammatory effects. However, there is no clear evidence that it has direct anti-inflammatory effects in the liver. This study showed that lobeglitazone reduces LPS-induced NLPR3 inflammasome activation and production of proinflammatory cytokines in primary KCs and hepatocytes. Cytokines secreted by activated KCs increased hepatocyte inflammation and HSC activation, and lobeglitazone inhibited these responses. In addition, lobeglitazone suppressed liver fibrosis by inhibiting LPS-induced transforming growth factor (TGF)-β secretion and TGF-β-induced CTGF expression. The inhibitory effect of lobeglitazone on inflammasome activation was associated with suppression of liver fibrosis. These results suggest that lobeglitazone may be a treatment option for inflammation and fibrosis in the liver.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, School of Medicine, Institute for Medical Science, Keimyung University, Daegu, Korea.
- Department of Physiology, University of Washington, Seattle, WA, United States of America.
ORCID-Profile: Byoung Kuk Jang
Förderung
- National Research Foundation of Korea
Zitieren
APA
Seo, H. Y., Lee, S. H., Park, J. Y., Han, E., Han, S., Hwang, J. S., Kim, M. K., & Jang, B. K. (2023). Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver. PLOS ONE. https://doi.org/10.1371/journal.pone.0290532
Vancouver
Seo HY, Lee SH, Park JY, Han E, Han S, Hwang JS, et al. Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver. PLOS ONE. 2023. doi:10.1371/journal.pone.0290532
BibTeX
@article{Seo2023,
author = {Seo, Hye-Young and Lee, So-Hee and Park, Ji Yeon and Han, Eugene and Han, Sol and Hwang, Jae Seok and Kim, Mi Kyung and Jang, Byoung Kuk},
title = {Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0290532}
}
EUVIMED